Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Frontiers in Oncology
|
May 27, 2024
A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)
Amina Maimaitiaili, Yijun Li, Na Chai, et al.
Breast (Edinburgh, Scotland)
|
January 26, 2024
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Xuhui Guo, Jiao Zhang, Xilong Gong, et al.
Eclinicalmedicine
|
September 29, 2020
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
Jianbin Li, Haibo Wang, Cuizhi Geng, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
|
May 16, 2024
Efficacy and safety of margetuximab plus chemotherapy <i>vs.</i> trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
Qingyuan Zhang, Quchang Ouyang, Wei Li, et al.
JAMA
|
December 13, 2024
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial
Li Chen, Hui Li, Hao Zhang, et al.
Breast (Edinburgh, Scotland)
|
June 26, 2024
The features of male breast cancer in China: A real-world study
Yuxuan Gao, Mengmeng Zhang, Gang Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2020
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Junjie Li, Keda Yu, Da Pang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
Patricia A Ganz, Hanna Bandos, Tanja Španić, et al.
Cancer
|
August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China
Chunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Nature Medicine
|
January 8, 2024
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Zefei Jiang, Quchang Ouyang, Tao Sun, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Frontiers in Oncology
|
May 27, 2024
A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)
Amina Maimaitiaili, Yijun Li, Na Chai, et al.
Breast (Edinburgh, Scotland)
|
January 26, 2024
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Xuhui Guo, Jiao Zhang, Xilong Gong, et al.
Eclinicalmedicine
|
September 29, 2020
Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020
Jianbin Li, Haibo Wang, Cuizhi Geng, et al.
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer
|
May 16, 2024
Efficacy and safety of margetuximab plus chemotherapy <i>vs.</i> trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study
Qingyuan Zhang, Quchang Ouyang, Wei Li, et al.
JAMA
|
December 13, 2024
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial
Li Chen, Hui Li, Hao Zhang, et al.
Breast (Edinburgh, Scotland)
|
June 26, 2024
The features of male breast cancer in China: A real-world study
Yuxuan Gao, Mengmeng Zhang, Gang Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2020
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Junjie Li, Keda Yu, Da Pang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
Patricia A Ganz, Hanna Bandos, Tanja Španić, et al.
Cancer
|
August 2, 2024
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China
Chunwei Xu, Zhanhong Chen, Yuanli Xia, et al.
Nature Medicine
|
January 8, 2024
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
Zefei Jiang, Quchang Ouyang, Tao Sun, et al.
Page
of 8